1. Home
  2. PHAT vs NPKI Comparison

PHAT vs NPKI Comparison

Compare PHAT & NPKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • NPKI
  • Stock Information
  • Founded
  • PHAT 2018
  • NPKI 1932
  • Country
  • PHAT United States
  • NPKI United States
  • Employees
  • PHAT N/A
  • NPKI N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • NPKI Metal Fabrications
  • Sector
  • PHAT Health Care
  • NPKI Industrials
  • Exchange
  • PHAT Nasdaq
  • NPKI Nasdaq
  • Market Cap
  • PHAT 942.6M
  • NPKI 1.0B
  • IPO Year
  • PHAT 2019
  • NPKI N/A
  • Fundamental
  • Price
  • PHAT $14.85
  • NPKI $11.60
  • Analyst Decision
  • PHAT Strong Buy
  • NPKI Strong Buy
  • Analyst Count
  • PHAT 5
  • NPKI 3
  • Target Price
  • PHAT $17.60
  • NPKI $14.17
  • AVG Volume (30 Days)
  • PHAT 983.2K
  • NPKI 966.4K
  • Earning Date
  • PHAT 10-30-2025
  • NPKI 10-30-2025
  • Dividend Yield
  • PHAT N/A
  • NPKI N/A
  • EPS Growth
  • PHAT N/A
  • NPKI N/A
  • EPS
  • PHAT N/A
  • NPKI 0.38
  • Revenue
  • PHAT $147,190,000.00
  • NPKI $259,372,000.00
  • Revenue This Year
  • PHAT $218.38
  • NPKI $21.14
  • Revenue Next Year
  • PHAT $87.14
  • NPKI $9.42
  • P/E Ratio
  • PHAT N/A
  • NPKI $31.14
  • Revenue Growth
  • PHAT 460.30
  • NPKI 25.65
  • 52 Week Low
  • PHAT $2.21
  • NPKI $4.76
  • 52 Week High
  • PHAT $16.08
  • NPKI $14.00
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 64.62
  • NPKI 41.69
  • Support Level
  • PHAT $14.12
  • NPKI $11.50
  • Resistance Level
  • PHAT $15.28
  • NPKI $12.09
  • Average True Range (ATR)
  • PHAT 0.93
  • NPKI 0.62
  • MACD
  • PHAT 0.07
  • NPKI -0.20
  • Stochastic Oscillator
  • PHAT 82.58
  • NPKI 18.57

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About NPKI NPK International Inc. Common Stock

NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.

Share on Social Networks: